Lung Cancer Susceptibility malady

MalaCards: Lung Cancer Susceptibility, also known as carcinoma of lung, is related to squamous cell carcinoma and lung cancer susceptibility 2. An important gene associated with Lung Cancer Susceptibility is LNCR3 (Lung cancer susceptibility 3), and among its related pathways are Carbamazepine Pathway, Pharmacokinetics and Caffeine metabolism. The compounds egcg and 1-hydroxypyrene have been mentioned in the context of this disorder. Affiliated tissues include lung, t cells and b cells, and related mouse phenotypes are endocrine/exocrine gland and liver/biliary system.

lung cancer susceptibility 33 carcinoma of lung 43

Disease types for lung cancer susceptibility family:

lung cancer susceptibility 3	lung cancer susceptibility 4
lung cancer susceptibility 2

Diseases related to lung cancer susceptibility by text searches and GeneDecks gene sharing:

(show top 50)    (show all 446)

id	Related Disease	Score	Top Affiliating Genes
1	squamous cell carcinoma	33.0	GSTP1, CYP2E1, CYP2D6, EGFR
2	lung cancer susceptibility 2	32.3	CHRNA3, CHRNA5
3	small cell carcinoma	30.0	RASSF1, GSTM1, GSTP1, FASLG, FAS, TP53
4	small-cell cancer of lung	27.6	MYCL1, RASSF1, FHIT, GSTM1, GSTP1, GSTT1
5	neuroendocrine carcinoma	27.5	MYCL1, CDKN1A, GSTP1, TP53, EGFR, OGG1
6	merkel cell carcinoma	26.6	MYCL1, RASSF1, CDKN1A, FHIT, TP53, POU2F1
7	ovarian mucinous neoplasm	26.4	CDKN1A, MLH1, GSTP1, IL1B, TP53, TERT
8	lung occult squamous cell carcinoma	25.9	CHRNA3, MPO, CDKN1A, MMP1, GSTM1, GSTP1
9	non-small cell lung carcinoma	24.9	RASSF1, CDKN1A, FHIT, GSTM1, GSTP1, FASLG
10	lung carcinoma	21.9	MYCL1, RASSF1, XRCC1, XRCC6, ATM, MPO
11	carcinoma	19.3	NAT1, NAT2, MYCL1, RASSF1, LIG4, CLPTM1L
12	thyroiditis	16.9	NAT2, MYCL1, RASSF1, LIG4, MTHFR, XRCC1
13	orolaryngeal cancer	13.7	GSTM1, OGG1, EPHX1
14	substance dependence	13.6	CHRNA3, GSTM1, GSTP1, CHRNA5
15	porphyria cutanea tarda	13.6	GSTM1, GSTT1, CYP1A1, CYP2E1
16	alcoholic liver cirrhosis	13.6	NAT2, GSTM1, CYP2A6, CYP2E1
17	nicotine dependence	13.6	CHRNA3, CYP2A6, CYP2E1, CYP2D6, CHRNA5
18	xeroderma pigmentosum, group d	13.5	XRCC1, XRCC4, ERCC2
19	diffuse gastric cancer	13.5	GSTM1, GSTP1, GSTT1, ERCC2, ERCC1
20	secondary syphilis	13.5	CYP1B1, CYP2A6, CYP2C19
21	exfoliation syndrome	13.4	MPO, GSTM1, GSTP1, GSTT1
22	ehlers-danlos syndrome	13.4	XRCC1, GSTM1, GSTP1, GSTT1, ERCC2
23	alcoholic pancreatitis	13.4	NAT2, GSTM1, GSTP1, GSTT1, CYP2E1, NQO1
24	myoma	13.4	XRCC4, ERCC2, TERT, EGFR
25	microtia	13.4	XRCC1, XRCC4, ERCC2
26	dna ligase iv deficiency	13.3	LIG4, XRCC4, XRCC5, ATR
27	open-angle glaucoma	13.3	MMP1, GSTM1, GSTT1, CYP1B1
28	acoustic neuroma	13.3	LIG4, XRCC1, XRCC4, APEX1, ERCC2, OGG1
29	neuroma	13.3	LIG4, XRCC1, XRCC4, APEX1, ERCC2, OGG1
30	substance abuse	13.3	NAT1, CYP2C19, CYP2E1, CYP2D6
31	motor neuron disease	13.2	NAT1, NAT2, GSTM1, GSTP1, GSTT1, CYP2E1
32	tardive dyskinesia	13.1	GSTM1, GSTP1, GSTT1, GPX1, CYP1A1, CYP2C19
33	hereditary pancreatitis	13.1	ATR, ATM, GSTM1, GSTP1, GSTT1, TP53BP1
34	growth retardation with deafness and mental retardation due to igf1 deficiency	13.1	LIG4, XRCC5, ATR, ATM, TP53BP1
35	li-fraumeni syndrome	13.1	NAT2, FHIT, CYP1A1, CYP1B1
36	variegate porphyria	13.1	GSTM1, GSTT1, CYP1A1, CYP1B1, CYP2A6, CYP2C19
37	diabetic neuropathy	13.1	GSTM1, GSTT1, IL1B, GPX1, CYP2D6
38	stomach carcinoma	13.1	RASSF1, MLH1, FAS
39	birth defects	13.0	MTHFR, SULT1A1, CYP2E1, EPHX1
40	asbestosis	13.0	MPO, CDKN1A, GSTM1, GSTP1, GSTT1, OGG1
41	multiple chemical sensitivity	13.0	NAT1, NAT2, MTHFR, CYP2D6
42	autoimmune hepatitis	13.0	GSTT1, FAS, CYP2D6, CYP2C9
43	alpha 1-antitrypsin deficiency	13.0	MPO, MMP1, GSTP1, EPHX1
44	gastritis	13.0	MLH1, GSTT1, TERT
45	sycp3-related pregnancy loss, susceptibility to	13.0	MTHFR, GSTT1, CYP1A1, CYP1B1
46	leukopenia	13.0	LIG4, MPO, GSTM1, GSTT1, IL1B
47	clubfoot	12.9	NAT1, NAT2, MTHFR, CYP1A1, EPHX1
48	familial prostate cancer	12.9	MLH1, GSTM1, GSTP1, GSTT1, SULT1A1, CYP1A1
49	diabetic polyneuropathy	12.9	GSTM1, GSTT1, GPX1, TP53
50	drug-induced hepatitis	12.9	NAT1, NAT2, GSTM1, GSTT1, CYP2C19, CYP2E1

Approved drugs:

Drug clinical trials:

MalaCards organs/tissues related to lung cancer susceptibility:

²²

MGI Mouse Phenotypes related to lung cancer susceptibility:

²⁵ (show all 16)

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	endocrine/exocrine gland phenotype	MP:0005379	9.9	FASLG, ERCC1, EXO1, XRCC4
2	liver/biliary system phenotype	MP:0005370	9.3	POU2F1, APEX1, EGFR, NQO1, CYP2E1, TERF2
3	reproductive system phenotype	MP:0005389	8.7	ERCC2, EXO1, CAMKK1, FASLG, MLH1, ATR
4	hematopoietic system phenotype	MP:0005397	7.7	PRKDC, ATM, ERCC1, FHIT, CDKN1A, LIG4
5	immune system phenotype	MP:0005387	7.4	ATM, FHIT, TERT, GPX1, ERCC2, ERCC1
6	nervous system phenotype	MP:0003631	7.4	BAG6, PRKDC, EGFR, TERT, ERCC2, CAMKK1
7	skeleton phenotype	MP:0005390	7.2	FAS, ERCC2, ERCC1, TP53, TERT, EGFR
8	behavior/neurological phenotype	MP:0005386	6.7	POU2F1, LIG4, GRPR, CAMKK1, ATR, TP53
9	digestive/alimentary phenotype	MP:0005381	6.6	XRCC5, FHIT, PRKDC, EGFR, FAS, TERT
10	integument phenotype	MP:0010771	6.6	GSTP1, POU2F1, EGFR, TP53, XRCC4, ERCC1
11	vision/eye phenotype	MP:0005391	6.5	GPX1, MTHFR, XRCC5, MMP2, FASLG, CDKN1A
12	mortality/aging	MP:0010768	6.0	ATR, MTHFR, BAG6, CHRNA3, RASSF1, ATM
13	growth/size phenotype	MP:0005378	5.7	CHRNA3, POU2F1, XRCC1, XRCC4, XRCC5, XRCC6
14	cellular phenotype	MP:0005384	5.6	EGFR, PRKDC, TERF2, GSTM1, APEX1, FASLG
15	tumorigenesis	MP:0002006	3.6	COL18A1, PRKDC, IL1B, GSTP1, FHIT, MLH1
16	homeostasis/metabolism phenotype	MP:0005376	2.7	GRPR, GSTM1, FHIT, MLH1, MMP2, CDKN1A

Articles related to lung cancer susceptibility:

(show top 50)    (show all 66)

id	Title	Authors	Year	Affiliating Genes
1	HapMap-based study of a region encompassing ERCC1 and ERCC2 related to lung cancer susceptibility in a Chinese population. (21601580)	Yin J.... Song T.	2011	ERCC2, ERCC1
2	Meta-analysis of the relationship between p21 Ser31Ar g polymorphism and lung cancer susceptibility. (22009857)	Lin G.... Yu L.	2011	CDKN1A
3	A meta analysis on the relationship between myeloper oxidase G-463A genetic polymorphisms and lung cancer susceptibility]. (20673504)	Hua F.... Zhou Q.	2010	MPO
4	A polymorphism in the hMLH1 gene (-93G-->A) associ ated with lung cancer susceptibility and prognosis. (19956916)	Shih C.M.... Wang Y.C.	2010	MLH1
5	Polymorphisms in the microsomal epoxide hydrolase gen e: role in lung cancer susceptibility and prognosis. (21302624)	Erkisi Z.... Isbir T.	2010	EPHX1
6	International Lung Cancer Consortium: coordinated ass ociation study of 10 potential lung cancer susceptibility variants. (20106900)	Truong T.... Hung R.J.	2010	TP53, FAS, IL1B
7	Lung cancer susceptibility and prognosis associated with polymorphisms in the nonhomologous end-joining pathway genes: a multiple genotype-phenotype study. (19408343)	Tseng R.C.... Wang Y.C.	2009	LIG4, XRCC6, XRCC4
8	Functional characterization of a promoter polymorphis m in APE1/Ref-1 that contributes to reduced lung cancer susceptibility. (19541747)	Lu J.... Lu D.	2009	APEX1, POU2F1
9	Lung cancer susceptibility and genetic polymorphisms of Exo1 gene in Taiwan. (19331228)	Hsu N.Y.... Bau D.T.	2009	EXO1
10	Genetic variation in telomere maintenance genes, telomere length, and lung cancer susceptibility. (19285750)	Hosgood H.D.... Lan Q.	2009	TERT, TERF2, POT1
11	Lung cancer susceptibility and genetic polymorphism o f DNA repair gene XRCC4 in Taiwan. (19729825)	Hsu N.Y.... Bau D.T.	2009	XRCC4
12	The association between RASSF1 gene polymorphisms and lung cancer susceptibility among people in Hubei Province of China. (19821102)	Xiao G.... Wu G.	2009	RASSF1
13	An investigation of the relationship between SULT1A1 Arg(213)His polymorphism and lung cancer susceptibility in a Turkish population. (19350537)	Arslan S.... Pinarbasi H.	2009	SULT1A1
14	CYP2D6*10 polymorphisms and lung cancer susceptibility (19024387)	Yan Z.... Wu Y.J.	2008	CYP2D6
15	The association of OGG1 Ser326Cys polymorphism and urinary 8-OHdG levels with lung cancer susceptibility: a hospital-based case-control study in Turkey. (19064361)	Karahalil B.... Karakaya A.E.	2008	OGG1
16	Pathway-based evaluation of 380 candidate genes and lung cancer susceptibility suggests the importance of the cell cycle pathway. (18676680)	Hosgood H.D.... Lan Q.	2008	GRPR
17	A polymorphism in the angiogenesis inhibitor, endostatin, in lung cancer susceptibility. (18054814)	Zambon L.... Lima C.S.	2008	COL18A1
18	Tagging single nucleotide polymorphisms in phosphoinositide-3-kinase-related protein kinase genes involved in DNA damage 'checkpoints' and lung cancer susceptibility. (18451257)	Hu Z.... Shen H.	2008	ATM, ATR, PRKDC
19	Lung cancer susceptibility locus at 5p15.33. (18978790)	McKay J.D.... Brennan P.	2008	TERT, CHRNA3, CLPTM1L
20	CYP1A1 *2B and *4 polymorphisms are associated with lung cancer susceptibility in Mexican patients. (18409147)	Gallegos-Arreola M.P.... Zuniga-Gonzalez G.M.	2008	CYP1A1
21	GST genotypes and lung cancer susceptibility in Asian populations with indoor air pollution exposures: a meta-analysis. (17428724)	Hosgood H.D.... Lan Q.	2007	GSTP1, GSTT1, GSTM1
22	Combined effects of genetic polymorphisms in cytochrome P450s and GSTM1 on lung cancer susceptibility (18261353)	Gu Y.F.... Gu S.X.	2007	CYP1A1, CYP2D6, GSTM1
23	Combined effects of genetic polymorphisms in six selected genes on lung cancer susceptibility. (17428572)	Yang M.... Lee J.S.	2007	GSTP1, CYP1A1, MPO
24	Genetic polymorphisms of phase II metabolic enzymes and lung cancer susceptibility in a population of Central South China. (16788248)	Chen H.C.... Liu J.	2006	GSTP1, GSTT1, GSTM1
25	Lung cancer susceptibility in Fhit-deficient mice is increased by Vhl haploinsufficiency. (16061637)	Zanesi N.... Huebner K.	2005	FHIT
26	'Comparison of extremes' approach provides evidence against the modifying role of NAT2 polymorphism in lung cancer susceptibility. (15808403)	Belogubova E.V.... Imyanitov E.N.	2005	NAT2
27	Rapid detection of single nucleotide polymorphisms related with lung cancer susceptibility of Chinese population. (15896461)	Liang G.... Yin L.	2005	GSTP1, CYP1B1, OGG1
28	Possible risk modification by CYP1A1, GSTM1 and GSTT1 gene polymorphisms in lung cancer susceptibility in a South Indian population. (16228113)	Sreeja L.... Ankathil R.	2005	CYP1A1, GSTT1, GSTM1
29	Functional haplotypes in the promoter of matrix metalloproteinase-2 and lung cancer susceptibility. (15731163)	Zhou Y.... Lin D.	2005	MMP2
30	Lung cancer susceptibility and polymorphisms of glutathione-S-transferase genes in Hong Kong. (15246186)	Chan-Yeung M.... Lam W.K.	2004	GSTP1, GSTT1, GSTM1
31	Genetic polymorphism of the CYP1A1, CYP2E1, GSTM1 and GSTT1 genes and lung cancer susceptibility in a north indian population. (15646021)	Sobti R.C.... Janmeja A.	2004	CYP1A1, GSTT1, GSTM1
32	Studies of the genes related to lung cancer susceptibility in Nanjing Han population, China. (15640066)	Liang G.Y.... Yin L.H.	2004	GSTP1, CYP1A1, GSTT1
33	Genetic polymorphism of the human cytochrome CYP2A13 in a French population: implication in lung cancer susceptibility. (15063809)	Cauffiez C.... Broly F.	2004	CYP2A13
34	A major lung cancer susceptibility locus maps to chromosome 6q23-25. (15272417)	Bailey-Wilson J.E.... Anderson M.W.	2004	LNCR1
35	Smoking and the risk of lung cancer: susceptibility with GSTP1 polymorphisms. (14501269)	Miller D.P.... Christiani D.C.	2003	GSTP1
36	Counterpoint: the myeloperoxidase -463G-->a polymorphism does not decrease lung cancer susceptibility in Caucasians. (12496043)	Xu L.L.... Christiani D.C.	2002	MPO
37	Genetic polymorphisms of glutathione S-transferases as modulators of lung cancer susceptibility. (12189190)	Stucker I.... Loriot M.A.	2002	GSTP1, GSTT1, GSTM1
38	Association of L-myc polymorphism with lung cancer susceptibility and prognosis in relation to age-selected controls and stratified cases. (11955646)	Shih C.M.... Wang Y.C.	2002	MYCL1
39	Genetic polymorphisms and lung cancer susceptibility: a review. (12234692)	Kiyohara C.... Hopkin J.M.	2002	GSTP1, TP53, CYP1A1
40	p53 Genotypes and Haplotypes Associated With Lung Cancer Susceptibility and Ethnicity. (11983757)	Wu X.... Spitz M.R.	2002	TP53
41	A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. (11691799)	Zhu Y.... Wu X.	2001	MMP1
42	CYP1A1, CYP2E1 and GSTM1 genetic polymorphisms. The effect of single and combined genotypes on lung cancer susceptibility in Chilean people. (11675150)	Quinones L.... Gil L.	2001	CYP1A1, GSTM1, CYP2E1
43	Relevance of N-acetyltransferase 1 and 2 (NAT1, NAT2) genetic polymorphisms in non-small cell lung cancer susceptibility. (11266080)	Wikman H.... Risch A.	2001	NAT1, NAT2
44	Lung cancer susceptibility in relation to combined polymorphisms of microsomal epoxide hydrolase and glutathione S-transferase P1. (11597790)	To-Figueras J.... Corbella J.	2001	GSTP1, GSTT1, GSTM1
45	Lack of evidence of association of p21WAF1/CIP1 polymorphism with lung cancer susceptibility and prognosis in Taiwan. (10744039)	Shih C.M.... Wang Y.C.	2000	CDKN1A
46	hOGG1 Ser326Cys polymorphism and lung cancer susceptibility. (10744126)	Sugimura H.... Yokota J.	1999	OGG1
47	p53 codon 72 polymorphism in Taiwanese lung cancer patients: association with lung cancer susceptibility and prognosis. (9918210)	Wang Y.C.... Lin P.	1999	TP53
48	Glutathione-S-Transferase M1 and codon 72 p53 polymorphisms in a northwestern Mediterranean population and their relation to lung cancer susceptibility. (9162298)	To-Figueras J.... Corbella J.	1996	GSTM1
49	Genetic polymorphisms of drug-metabolizing enzymes and lung cancer susceptibility. (7581493)	Kawajiri K.... Hayashi S.	1995	CYP1A1
50	Glutathione S-transferase mu locus: use of genotyping and phenotyping assays to assess association with lung cancer susceptibility. (1680031)	Zhong S.... Spurr N.K.	1991	GSTM1

Genes related to lung cancer susceptibility according to GeneCards:

(show top 50)    (show all 63)

id	Symbol	Description	Score	GeneCards Section Context
1	LNCR3	Lung cancer susceptibility 3	11.1	Aliases & Descriptions
2	LNCR4	Lung cancer susceptibility 4	11.1	Aliases & Descriptions
3	LNCR5	Lung cancer susceptibility 5	11.0	Aliases & Descriptions
4	EGFR	epidermal growth factor receptor	11.0	Publications
5	CHRNA5	cholinergic receptor, nicotinic, alpha 5 (neuronal)	11.0	Publications
6	CHRNA3	cholinergic receptor, nicotinic, alpha 3 (neuronal)	11.0	Publications
7	LNCR1	Lung cancer 1	11.0	Publications
8	MIR605	microRNA 605	11.0	Publications
9	MIR149	microRNA 149	11.0	Publications
10	MYCL1	v-myc myelocytomatosis viral oncogene homolog 1, lung carcinoma derived (avian)	11.0	Publications
11	EPHX1	epoxide hydrolase 1, microsomal (xenobiotic)	11.0	Publications
12	CAMKK1	calcium/calmodulin-dependent protein kinase kinase 1, alpha	11.0	Publications
13	BAG6	BCL2-associated athanogene 6	11.0	Publications
14	CYP2A13	cytochrome P450, family 2, subfamily A, polypeptide 13	11.0	Publications
15	TERF2	telomeric repeat binding factor 2	11.0	Publications
16	CLPTM1L	CLPTM1-like	11.0	Publications
17	LIG4	ligase IV, DNA, ATP-dependent	11.0	Publications
18	GRPR	gastrin-releasing peptide receptor	11.0	Publications
19	GPX1	glutathione peroxidase 1	11.0	Publications
20	GSTM1	glutathione S-transferase mu 1	11.0	Publications
21	ERCC2	excision repair cross-complementing rodent repair deficiency, complementation group 2	11.0	Publications
22	EXO1	exonuclease 1	11.0	Publications
23	CYP1A1	cytochrome P450, family 1, subfamily A, polypeptide 1	11.0	Publications
24	POT1	protection of telomeres 1 homolog (S. pombe)	11.0	Publications
25	OGG1	8-oxoguanine DNA glycosylase	11.0	Publications
26	NQO1	NAD(P)H dehydrogenase, quinone 1	11.0	Publications
27	CYP2E1	cytochrome P450, family 2, subfamily E, polypeptide 1	11.0	Publications
28	NAT2	N-acetyltransferase 2 (arylamine N-acetyltransferase)	11.0	Publications
29	GSTT1	glutathione S-transferase theta 1	11.0	Publications
30	NAT1	N-acetyltransferase 1 (arylamine N-acetyltransferase)	11.0	Publications
31	TP53BP1	tumor protein p53 binding protein 1	11.0	Publications
32	XRCC1	X-ray repair complementing defective repair in Chinese hamster cells 1	11.0	Publications
33	SULT1A1	sulfotransferase family, cytosolic, 1A, phenol-preferring, member 1	11.0	Publications
34	RASSF1	Ras association (RalGDS/AF-6) domain family member 1	11.0	Publications
35	CYP2A6	cytochrome P450, family 2, subfamily A, polypeptide 6	11.0	Publications
36	AKAP9	A kinase (PRKA) anchor protein (yotiao) 9	11.0	Publications
37	GSTP1	glutathione S-transferase pi 1	11.0	Publications
38	CYP2D6	cytochrome P450, family 2, subfamily D, polypeptide 6	11.0	Publications
39	ERCC1	excision repair cross-complementing rodent repair deficiency, complementation group 1 (includes overlapping antisense sequence)	11.0	Publications
40	APEX1	APEX nuclease (multifunctional DNA repair enzyme) 1	11.0	Publications
41	COL18A1	collagen, type XVIII, alpha 1	11.0	Publications
42	CYP1B1	cytochrome P450, family 1, subfamily B, polypeptide 1	11.0	Publications
43	POU2F1	POU class 2 homeobox 1	11.0	Publications
44	ATR	ataxia telangiectasia and Rad3 related	11.0	Publications
45	TERT	telomerase reverse transcriptase	11.0	Publications
46	XRCC4	X-ray repair complementing defective repair in Chinese hamster cells 4	11.0	Publications
47	XRCC5	X-ray repair complementing defective repair in Chinese hamster cells 5 (double-strand-break rejoining)	11.0	Publications
48	XRCC6	X-ray repair complementing defective repair in Chinese hamster cells 6	11.0	Publications
49	CYP2C19	cytochrome P450, family 2, subfamily C, polypeptide 19	11.0	Publications
50	FASLG	Fas ligand (TNF superfamily, member 6)	11.0	Publications

Pathways related to lung cancer susceptibility according to GeneDecks:

(show top 50)    (show all 79)

id	Pathway	Score	Top Affiliating Genes
1	Carbamazepine Pathway, Pharmacokinetics34	10.6	CYP2A6, EPHX1, CYP2E1
2	Caffeine metabolism20	10.4	NAT1, NAT2, CYP2A6, CYP2A13
3	2-Naphthylamine and 2-Nitronaphtalene metabolism10	10.3	CYP1A1, EPHX1, CYP2E1, SULT1A1
4	2-Naphthylamine and 2-Nitronaphtalene metabolism41	10.3	EPHX1, CYP2E1, CYP1A1, SULT1A1
5	Telomere Extension by Telomerase36	10.2	POT1, TERT, XRCC5, TERF2
6	Caffeine Pathway, Pharmacokinetics34	10.2	CYP2E1, CYP2A6, NAT2, CYP2C9
7	Platinum Pathway, Pharmacokinetics/Pharmacodynamics34	10.2	NQO1, GSTT1, GSTP1, GSTM1, MPO
8	Phase II conjugation38	10.2	GSTM1, GSTP1, NAT2, NAT1
9	Benzo[a]pyrene metabolism10	10.1	GSTP1, CYP1A1, EPHX1, CYP2C9, CYP1B1
10	Benzo[a]pyrene metabolism41	10.1	CYP1B1, CYP2C9, CYP1A1, GSTP1, EPHX1
11	Androstenedione and testosterone biosynthesis and metabolism p.141	10.1	CYP2A13, CYP2C9, CYP2C19
12	Integration of provirus38	10.1	XRCC4, LIG4, XRCC6, XRCC5
13	Transcription P53 signaling pathway10	10.1	TP53, ATR, APEX1
14	Gefitinib Pathway, Pharmacokinetics34	10.1	CYP2C19, CYP2D6, CYP2C9, CYP1A1
15	Androstenedione and testosterone biosynthesis and metabolism p.110	10.1	CYP1A1, CYP2C9, CYP2A13, CYP2C19
16	Acetaminophen metabolism41	10.0	CYP1A1, CYP2A6, CYP2E1, CYP2D6, CYP2A13, NQO1
17	Acetaminophen metabolism10	10.0	NQO1, GSTP1, SULT1A1, CYP1A1, CYP2A6, CYP2E1
18	DNA damage_DNA-damage-induced responses41	10.0	ATR, ATM, PRKDC
19	Lymphocyte Signaling3	10.0	XRCC5, APEX1, FASLG, NQO1, GPX1
20	Tamoxifen Pathway, Pharmacokinetics34	10.0	CYP2D6, CYP2C19, SULT1A1, CYP2C9
21	Busulfan Pathway, Pharmacodynamics34	9.9	NAT1, NAT2, MLH1, GSTM1, APEX1, GSTP1
22	Fluoxetine Pathway, Pharmacokinetics34	9.9	CYP2D6, CYP2C19, CYP2C9
23	Naphthalene metabolism10	9.9	CYP2A6, CYP2C9, GSTM1, GSTP1, GSTT1, CYP1A1
24	Naphthalene metabolism41	9.9	GSTM1, GSTP1, GSTT1, CYP1A1, EPHX1, CYP2A6
25	Warfarin Pathway, Pharmacokinetics34	9.9	CYP2C9, CYP2C19, CYP1A1
26	Phenytoin Pathway, Pharmacokinetics34	9.9	NQO1, CYP2C9, CYP2A6, CYP2C19, CYP2E1, CYP2D6
27	Estradiol metabolism10	9.9	SULT1A1, CYP1A1, CYP2C19, CYP2C9, CYP2D6, CYP1B1
28	Estradiol metabolism41	9.9	CYP2C9, CYP2D6, CYP2C19, CYP1A1, SULT1A1, CYP1B1
29	Biological oxidations38	9.8	CYP1B1, CYP2D6, CYP2A13, CYP2C9, CYP2C19, CYP2A6
30	Doxorubicin Pathway (Cancer Cell), Pharmacodynamics34	9.8	MLH1, GPX1, ERCC2, TP53, NQO1
31	Non-homologous end-joining20	9.8	XRCC4, XRCC5, XRCC6, PRKDC, LIG4
32	DNA damage NHEJ mechanisms of DSBs repair10	9.8	XRCC6, XRCC5, PRKDC, XRCC4, LIG4
33	DNA damage_NHEJ mechanisms of DSBs repair41	9.8	XRCC6, XRCC5, XRCC4, LIG4, PRKDC
34	Retinol metabolism10	9.7	CYP2A6, CYP2D6, CYP2C9, CYP2E1, CYP1A1, CYP1B1
35	Retinol metabolism41	9.7	CYP2D6, CYP2C9, CYP1B1, CYP2E1, CYP2C19, CYP2A6
36	Cyclophosphamide Pathway, Pharmacokinetics34	9.7	CYP2C9, CYP2C19, CYP2A6
37	Retinol metabolism20	9.7	CYP2A13, CYP1A1, CYP2A6, CYP2C19, CYP2C9
38	Metabolism of xenobiotics by cytochrome P45020	9.6	CYP2C9, GSTM1, CYP2C19, GSTT1, CYP1A1, GSTP1
39	Drug metabolism - cytochrome P45020	9.6	GSTP1, GSTT1, CYP2A6, CYP2C19, CYP2E1, GSTM1
40	DNA damage DNA-damage-induced responses10	9.5	ATR, ATM, PRKDC, TP53
41	DNA damage_Role of Brca1 and Brca2 in DNA repair41	9.4	TP53BP1, TP53, ATM, MLH1, ATR
42	DNA damage Role of Brca1 and Brca2 in DNA repair10	9.4	ATM, MLH1, ATR, TP53, TP53BP1
43	Bladder cancer20	9.1	MMP2, RASSF1, CDKN1A, MMP1, TP53, EGFR
44	DNA Damage3	9.1	PRKDC, APEX1, TERF2, TP53BP1, TP53, ERCC1
45	Transcription_P53 signaling pathway41	8.9	TP53, ATR, ATM, ERCC2, CDKN1A, MMP2
46	Selected targets of GCR-alpha10	8.6	CYP2C9, CYP2C19, FASLG, IL1B, CDKN1A
47	DNA Repair Mechanisms36	8.5	OGG1, PRKDC, TP53, ERCC1, ERCC2, APEX1
48	Pathways in cancer20	8.4	EGFR, MMP2, GSTP1, RASSF1, MMP1, CDKN1A
49	p53 signaling pathway20	8.4	CDKN1A, ATM, FAS, TP53, ATR
50	Cell Cycle / Checkpoint Control3	7.8	GSTP1, XRCC1, XRCC5, XRCC6, ATR, ATM

Compounds related to lung cancer susceptibility according to GeneDecks:

(show top 50)    (show all 402)

id	Compound	Score	Top Affiliating Genes
1	egcg32	10.4	SULT1A1
2	1-hydroxypyrene32	10.1	NAT2, GSTM1, GSTP1, GSTT1, CYP2E1, NQO1
3	arylamine32	9.9	NAT1, NAT2, GSTM1, GSTT1, SULT1A1, CYP2C19
4	h2o232	9.9	NAT1, MPO, APEX1, GPX1, CYP1B1, NQO1
5	benzene32	9.8	NAT2, XRCC1, GSTM1, GSTT1, APEX1, SULT1A1
6	cotinine32 18	10.8	NAT2, XRCC1, GSTM1, GSTT1, ERCC2, CYP1B1
7	valproic acid32 34 9 18 9	13.6	EPHX1, CYP2C9, CYP2A13, CYP2E1, CYP2C19, CYP2A6
8	phenacetin32 9 9	11.6	SULT1A1, CYP1A1, CYP2A6, CYP2C19, CYP2E1, CYP2D6
9	debrisoquine32	9.6	CYP2A6, CYP1A1, GSTM1, NAT2, CYP2C19, CYP2E1
10	furafylline32	9.6	CYP1A1, CYP2C9, CYP2D6, CYP2E1, CYP2C19, CYP1B1
11	nadph32 18	10.6	CYP2A6, XRCC1, CYP2D6, OGG1, CYP1A1, CYP1B1
12	aflatoxin b132 18	10.6	EPHX1, CYP2A13, CYP2A6, NAT1, NAT2, GSTM1
13	bufuralol32 9 9	11.6	CYP2D6, CYP2E1, CYP2C19, CYP1B1, CYP2A6, CYP1A1
14	6-hydroxymelatonin32 18	10.6	CYP2A13, CYP2C9, CYP2E1, CYP1A1, CYP1B1, CYP2A6
15	chlorzoxazone32 9 9	11.5	CYP2C9, NQO1, NAT2, CYP1A1, CYP1B1, CYP2A6
16	hydrocarbons32	9.5	SULT1A1, CYP1A1, CYP1B1, CYP2C9, NQO1, EPHX1
17	coumarin32 18	10.5	CYP2C19, CYP2A6, CYP1B1, CYP2E1, CYP1A1, CYP2D6
18	paraxanthine32 18	10.4	CYP2C19, CYP2E1, CYP2D6, CYP2A13, CYP2C9, CYP2A6
19	parathion32 18	10.4	CYP2A6, CYP2E1, CYP1A1, CYP1B1, CYP2C19, CYP2D6
20	beta-naphthoflavone32 9 9	11.4	CYP2A6, CYP2D6, CYP1A1, NQO1, CYP2C9, CYP2E1
21	alpha-naphthoflavone32	9.4	CYP2D6, CYP2E1, CYP2C19, CYP2A6, CYP1B1, CYP1A1
22	bpde32	9.2	ATM, GSTM1, GSTP1, TP53, CYP1A1, EPHX1
23	ethoxyresorufin32	9.2	CYP2A6, CYP1B1, CYP2C19, CYP1A1, CYP2E1, CYP2C9
24	gsts32	9.0	NAT1, NAT2, MTHFR, XRCC1, GSTM1, GSTP1
25	epoxide32	8.8	CYP2E1, CYP2C19, CYP2D6, CYP2C9, NQO1, EPHX1
26	methylmethanesulfonate32	8.8	TP53BP1, APEX1, TP53, XRCC1, XRCC6, ATR
27	formaldehyde32 18	9.7	MPO, APEX1, CYP2D6, CYP2C9, CYP1B1, CYP1A1
28	benzo(a)pyrene32	8.5	NAT2, XRCC1, CDKN1A, GSTM1, GSTP1, GSTT1
29	caffeine32 34 9 18 9	12.4	NAT1, NAT2, ATR, ATM, TP53, TP53BP1
30	folate32	8.4	RASSF1, GSTP1, MLH1, MMP2, XRCC1, MTHFR
31	n acetylcysteine32	8.1	TERT, NQO1, EGFR, ATM, CDKN1A, MMP1
32	resveratrol32 9 18 9	11.0	MMP2, CYP2E1, NQO1, FASLG, EPHX1, FAS
33	tamoxifen32 34 9 9	10.8	CDKN1A, TP53, FAS, SULT1A1, EPHX1, EGFR
34	oxaliplatin32 34 9 9	10.5	MLH1, GSTM1, GSTP1, GSTT1, FAS, ERCC2
35	thymidylate32	7.5	MTHFR, XRCC1, CDKN1A, MLH1, GSTM1, GSTP1
36	gemcitabine32 34 9 9	10.5	MTHFR, NQO1, TP53, ERCC1, ERCC2, APEX1
37	curcumin32	7.4	CYP1A1, GSTP1, MMP1, IL1B, TP53, EGFR
38	etoposide32 42 9 9	10.4	XRCC1, ATR, ATM, CDKN1A, MMP2, MLH1
39	ascorbic acid32 18	8.4	FAS, CYP1A1, CYP2E1, NQO1, OGG1, FASLG
40	estrogen32	7.2	NAT1, NAT2, RASSF1, MTHFR, EPHX1, EGFR
41	oxygen32 18	8.1	NQO1, MLH1, GSTM1, GSTT1, APEX1, FAS
42	camptothecin32 42 9 9	9.9	TP53, TP53BP1, TERT, NQO1, PRKDC, FAS
43	testosterone32 9 18 9	9.8	CYP1A1, MMP2, CYP2C19, CYP2E1, CYP2D6, CYP2A13
44	doxorubicin32 34 9 9	9.7	GSTT1, FASLG, FAS, GPX1, ERCC1, TERT
45	genistein32 9 18 9	9.5	IL1B, MMP2, MMP1, GSTP1, FAS, FASLG
46	paclitaxel32 34 9 9	9.5	NAT1, CYP2C19, CYP2C9, EGFR, CYP2A6, CYP1B1
47	oligonucleotide32	6.5	NAT2, NAT1, TERT, SULT1A1, CYP1B1, CYP2C9
48	5fluorouracil32	6.3	ERCC2, MLH1, MMP2, GSTP1, FASLG, ERCC1
49	cisplatin32 34 9 9	8.4	EGFR, RASSF1, MTHFR, XRCC1, XRCC5, XRCC6
50	retinoic acid32 42 18	6.0	FAS, POU2F1, EGFR, CYP2C9, TP53, TERF2

Cellular components related to lung cancer susceptibility according to GeneDecks:

id	Name	GO ID	Score	Top Affiliating Genes
1	DNA ligase IV complex	GO:032807	10.2	XRCC4, LIG4
2	nuclear telomere cap complex	GO:000783	9.8	TERT, POT1, TERF2, XRCC6, XRCC5
3	chromosome, telomeric region	GO:000781	9.8	ATM, POT1, TERT, TP53BP1, TERF2
4	Ku70:Ku80 complex	GO:043564	9.7	XRCC6, XRCC5
5	nonhomologous end joining complex	GO:070419	9.6	XRCC5, XRCC4, LIG4, PRKDC, XRCC6
6	DNA-dependent protein kinase-DNA ligase 4 complex	GO:005958	9.6	PRKDC, XRCC6, XRCC5, LIG4, XRCC4
7	endoplasmic reticulum membrane	GO:005789	9.2	CYP1A1, CYP1B1, CYP2A6, CYP2C19, CYP2E1, CYP2D6
8	nucleoplasm	GO:005654	7.1	LIG4, TERF2, TP53, ERCC1, ERCC2, APEX1
9	cytosol	GO:005829	5.8	GSTT1, NAT1, NQO1, SULT1A1, TP53, AKAP9
10	nucleus	GO:005634	5.0	FAS, CAMKK1, POU2F1, LIG4, OGG1, EGFR

Biological processes related to lung cancer susceptibility according to GeneDecks:

(show all 35)

id	Name	GO ID	Score	Top Affiliating Genes
1	UV protection	GO:009650	10.4	GPX1, ERCC2, ERCC1
2	telomere maintenance via telomerase	GO:007004	10.3	POT1, TERF2, TERT
3	heterocycle metabolic process	GO:046483	10.3	CYP2C19, CYP2D6, CYP2E1
4	isotype switching	GO:045190	10.2	ERCC1, XRCC4, LIG4
5	immunoglobulin V(D)J recombination	GO:033152	10.2	XRCC4, LIG4, PRKDC
6	pro-B cell differentiation	GO:002328	10.2	PRKDC, XRCC4, LIG4
7	exogenous drug catabolic process	GO:042738	10.1	CYP2C19, CYP2A6, CYP2C9
8	positive regulation of neurogenesis	GO:050769	10.1	LIG4, XRCC4, XRCC6, XRCC5
9	response to X-ray	GO:010165	10.1	LIG4, ERCC1, XRCC4
10	monoterpenoid metabolic process	GO:016098	10.1	CYP2D6, CYP2E1, CYP2C19, CYP2C9
11	positive regulation of fibroblast proliferation	GO:048146	10.0	LIG4, XRCC4, CDKN1A, EGFR
12	response to oxidative stress	GO:006979	10.0	OGG1, NQO1, ERCC1, ERCC2, MPO
13	base-excision repair	GO:006284	9.9	TP53, APEX1, XRCC1, OGG1
14	steroid metabolic process	GO:008202	9.9	CYP2D6, CYP2C9, CYP2E1, CYP2A6, CYP2C19
15	drug metabolic process	GO:017144	9.9	CYP1A1, CYP2C9, CYP2D6, CYP2E1, CYP2C19, CYP2A6
16	double-strand break repair via nonhomologous end joining	GO:006303	9.8	XRCC4, LIG4, XRCC5, PRKDC, XRCC6
17	cellular response to lithium ion	GO:071285	9.8	FAS, XRCC4, LIG4
18	T cell differentiation in thymus	GO:033077	9.7	PRKDC, TP53, XRCC4, LIG4
19	telomere maintenance	GO:000723	9.7	TERT, XRCC5, XRCC6, TERF2, PRKDC, POT1
20	inflammatory cell apoptotic process	GO:006925	9.6	FASLG, FAS
21	response to toxin	GO:009636	9.5	CYP1B1, GPX1, EPHX1, FAS, CDKN1A, NQO1
22	chromosome organization	GO:051276	9.5	LIG4, ERCC1, TP53
23	neuron apoptotic process	GO:051402	9.4	LIG4, ATM, FAS, TP53
24	oxidation-reduction process	GO:055114	9.4	CYP2C9, CYP2D6, CYP2E1, CYP2C19, CYP1B1, CYP1A1
25	replicative senescence	GO:090399	9.4	ATR, TERT, CDKN1A, ATM, TP53
26	cell proliferation	GO:008283	9.4	TP53, ERCC1, EGFR, GRPR, ERCC2, XRCC5
27	response to DNA damage stimulus	GO:006974	9.2	ATM, ATR, RASSF1, TP53, TP53BP1, CDKN1A
28	negative regulation of apoptotic process	GO:043066	9.0	XRCC5, CDKN1A, ATM, EGFR, TP53, ERCC1
29	xenobiotic metabolic process	GO:006805	9.0	CYP2A6, CYP2C19, NAT1, NAT2, GSTM1, GSTP1
30	response to gamma radiation	GO:010332	8.9	IL1B, GPX1, TP53, PRKDC, LIG4, XRCC4
31	double-strand break repair	GO:006302	8.8	PRKDC, TP53BP1, TP53, ERCC1, ATM, XRCC6
32	DNA repair	GO:006281	8.5	XRCC5, OGG1, PRKDC, TP53BP1, ERCC1, ERCC2
33	anti-apoptosis	GO:006916	8.5	MPO, TERT, IL1B, FAS, GPX1, GSTP1
34	small molecule metabolic process	GO:044281	8.2	CYP2A13, CYP2D6, CYP2E1, CYP2C19, CYP2A6, CYP1B1
35	positive regulation of apoptotic process	GO:043065	8.0	IL1B, ATM, FASLG, FAS, PRKDC, TP53

Molecular functions related to lung cancer susceptibility according to GeneDecks:

(show all 17)

id	Name	GO ID	Score	Top Affiliating Genes
1	oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavopr	GO:016712	10.2	CYP2E1, CYP2A6, CYP1B1
2	double-stranded telomeric DNA binding	GO:003691	10.2	XRCC6, TERF2, XRCC5
3	aromatase activity	GO:070330	10.2	CYP2A13, CYP1A1, CYP1B1, CYP2D6
4	telomeric DNA binding	GO:042162	10.1	XRCC5, TERT, TERF2
5	oxygen binding	GO:019825	10.0	CYP1B1, CYP2C19, CYP2E1, CYP1A1
6	damaged DNA binding	GO:003684	10.0	ERCC1, XRCC1, OGG1, APEX1
7	(R)-limonene 6-monooxygenase activity	GO:052741	10.0	CYP2C9, CYP2C19
8	(S)-limonene 7-monooxygenase activity	GO:018676	9.9	CYP2C19, CYP2C9
9	monooxygenase activity	GO:004497	9.8	CYP1B1, CYP2E1, CYP2D6, CYP2C9, CYP2C19
10	oxidoreductase activity	GO:016491	9.7	CYP2C19, CYP2E1, CYP2D6, CYP2C9, CYP1A1, APEX1
11	protein C-terminus binding	GO:008022	9.7	XRCC4, LIG4, XRCC5, XRCC6, ERCC2, ERCC1
12	(S)-limonene 6-monooxygenase activity	GO:018675	9.7	CYP2C9, CYP2C19
13	iron ion binding	GO:005506	9.6	CYP2A13, CYP2C19, CYP2A6, CYP2C9, CYP1A1, CYP1B1
14	electron carrier activity	GO:009055	9.5	CYP2A6, CYP1B1, CYP1A1, CYP2C9, CYP2C19, CYP2E1
15	heme binding	GO:020037	9.3	CYP2A6, CYP1A1, CYP2C19, MPO, CYP1B1, CYP2C9
16	enzyme binding	GO:019899	9.2	TP53, CYP2E1, CYP2A6, PRKDC, EGFR, CYP2C19
17	protein binding	GO:005515	4.2	POT1, TP53BP1, TERF2, TERT, NQO1, COL18A1